Drugs / ROSMANTUZUMAB
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02482441 | Jul 2015 → Jan 2018 | refractory malignant neoplasm | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROSMANTUZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990031 ↗ |
| Known as | OMP-131R10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02482441 ↗ |
| Modality | Monoclonal antibody | “OMP-131R10, IgG1 humanized monoclonal antibody” NCT02482441 ↗ |
| Route | Intravenous | “OMP-131R10 will be administered IV on the first day of each 14-day cycle.” NCT02482441 ↗ |